Project Grant R03AI188351
Award Date
8/1/25
Completion Date
7/31/27
Dollars Obligated
$150K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
This Project Grant award of $444,125 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research at Duke University to investigate the impact of red cell exchange (RCE) procedures on neutrophil function in sickle cell disease (SCD) patients. The research aims to determine if RCE, which replaces abnormal sickle hemoglobin red blood cells with normal hemoglobin cells, can modulate neutrophil reactivity and function,...
This $265,347 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the development and initial validation of a point-of-care device by Functional Fluidics Inc., a minority-owned small business in Detroit, Michigan. The goal is to create a simple, stand-alone, and potentially CLIA-waived diagnostic system to assess red blood cell sickling under hypoxic conditions as an indicator of sickle cell...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $637,526 to Duke University to conduct research on the role of sickle red blood cells (RBCs) in activating neutrophils and promoting vaso-occlusion in sickle cell disease (SCD). The key objectives of the research are to: 1) delineate the characteristics of sickle RBCs that contribute to neutrophil activation, 2) examine the...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the Cardiovascular Diseases Research federal grant program (CFDA 93.837), aims to evaluate methods for improving the homing and engraftment efficiency of CD34+ cells from sickle cell disease (SCD) patients. The $128,100 award to the New York Blood Center, Inc. will support research to determine if co-infusing the CD34+ cells with their flow-through accessory cells, normally discarded after CD34+ cell...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $608,126 to the Regents of the University of Minnesota to develop and validate single-cell biomarkers for predicting clinical outcomes in sickle cell disease (SCD). The research aims to: 1) define the relationship between SCD adverse outcomes and single-cell biochemical/mechanical properties to identify the most promising biomarkers; 2) define the...
This $299,790 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the development of novel allosteric modulators of the thrombin receptor, protease-activated receptor 1 (PAR1), called Parmodulins, for the treatment of sickle cell disease (SCD). The project aims to identify optimized Parmodulins with improved potency and oral activity, and confirm their efficacy in mouse models of SCD, including...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 - Cardiovascular Diseases Research provides $432,431 to San Jose State University Research Foundation to conduct research on red blood cell (RBC) deformability as a potential biomarker for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). The 3-year project aims to use an ultra-high throughput microfluidic fractionator to sort RBC subpopulations and analyze their metabolic,...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $154,796 to Vanderbilt University Medical Center to utilize non-invasive neuroimaging methods to investigate cerebral oxygen utilization in adults with sickle cell disease (SCD). The research aims to: 1) assess how treatment-induced increases in hemoglobin levels impact cerebral blood flow and arterial-to-venous transit times in SCD...
This Project Grant award, valued at $607,535, was provided by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The grant supports research to investigate the effects of the breakdown product hemin on the pulmonary endothelium and its contribution to the pulmonary complications of sickle cell disease, including acute chest syndrome and pulmonary hypertension. The research aims to evaluate the specific effects of...
This $3,292,001.00 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports the production of cultured red blood cells for sickle cell disease patient support at the Albert Einstein College of Medicine in Bronx, NY. The award, which spans from June 1, 2025 to May 31, 2029, aims to advance research and develop potential therapeutic interventions for sickle cell disease, a genetic blood disorder that primarily affects...